Exemplary instances include the favorable outcomes observed with PD-1 inhibitors, notably pembrolizumab and nivolumab, showcasing both effectiveness and tolerability in advanced HCC cases [38]. Here, PDCD1 is linked to hepatocellular carcinoma.